A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.

Trial Profile

A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs IdeS (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 Combined results of trials ( NCT02224820, NCT02426684, NCT02475551) assessing the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor.published in the New England Journal of Medicine
    • 02 Aug 2017 According to a Hansa Medical media release, combined results from this and 2 other trials (CT 244081and 230633) have been published in the New England Journal of Medicine.
    • 20 Jul 2017 According to a Hansa Medical media release, the company expects to enrol and treat all patients by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top